Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and IsraelTopline results are expected during the fourth quarter of 2021 HAIFA, Israel,...
-
HAIFA, Israel, May 25, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced the receipt of a “Disbursement...
-
New therapy has potential to generate improved blood counts in all three blood cell lineages, a meaningful advantage over existing treatmentsThe company will conduct an analyst and investor call on...
-
HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
-
HAIFA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
-
HAIFA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
-
HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
-
The CLI study is unlikely to meet its primary endpoint by the time of the final analysis Substantial low number of events in the placebo group in the CLI study decreased the statistical power of the...
-
PLX-R18 demonstrated significant clinical improvements in Hb, ANC, and PLT among the high-dose cohortPLX-R18 was found to be safe and well-toleratedTopline results from the full Phase I clinical trial...
-
HAIFA, Israel, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...